title: First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice.
authors.affiliation: Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
authors.forename: Charles A
authors.initials: CA
authors.lastname: Schiffer
mesh_terms: D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D011743:Pyrimidines; D000068877:Imatinib Mesylate